News | Coronavirus (COVID-19) | July 09, 2020

Free Web-based Lung and COVID-19 Imaging Data Management System Offered by PenRad

Vendor offering solution to help provide relief for busy imaging centers during COVID-19 crisis

A lung CT of a COVID-19 patient, showing ground-glass opacities in the lung from COVID pneumonia. Image courtesy of John Kim.

A lung CT of a COVID-19 patient, showing ground-glass opacities in the lung from COVID pneumonia. Image courtesy of John Kim.

July 9, 2020 — With increased lung CT exam paradigms being used in the current COVID-19 (SARS-CoV-2) outbreak, and an increase in lung nodules and incidental findings to be monitored for years, PenRad Technologies Inc. has decided to donate PenLung, its web-based lung CT tracking software ecosystem to U.S. diagnostic imaging centers. PenRad structured reporting allows for easy access to all patients with a diagnosis of COVID-19, incidental findings on lung CT exams and digital chest X-rays and facilitates long term follow-up of both.

"In light of the current COVID-19 pandemic and based on some of the early literature focused on lung abnormalities demonstrated on CT exams brought about by the disease, we have updated our software to track key information in the patients likely long term journey, specific to COVID-19,” said Greg Gustafson, PenRad founder and CEO. “In light of the current pressures in diagnostic imaging and what’s sure to be an oncoming increase in procedure volume, we have decided to provide this software platform to diagnostic imaging centers at no charge through 2020.”

PenRad’s secure, web-based software ecosystem is secure and easily accessible by diagnostic imaging centers, the platform streamlines the overall patient experience and offloads a significant portion of the work typically performed by technologists allowing them more time to focus on patients and patient throughput.  

"In this time of need as our front-line healthcare providers are looking for ways to streamline their typical workflow, stay safe and ease patient anxiety, PenRad is helping with removing the time-consuming burden of long-term tracking of patient data, freeing technologists to work with patients,” Gustafson said. “Keeping track of patient data, including lung nodules, structural changes and incidental findings, alone generates additional burden and liability for imaging facilities and radiologists. Add to this, a likely significant increase in lung computed tomography (CT) exams, and programs can quickly become overburdened. We are here to do our part to help in the follow-up of COVID-19 lung disease and incidental findings.”

Diagnostic imaging centers should contact PenRad today, and we will set up a facility account instantly on our Web server and get your team started with PenLung. All fees waived until Dece. 31, 2020.

PenRad offers solutions for breast imaging and PenLung, LDCT lung screening (updated to included COVID-19 induced findings) to enhance practice workflow. Designed for flexibility and easy integration PenRad’s client/server SQL enterprise architecture supports all customers ranging from individual imaging facilities to enterprise systems, while maintaining individual statistics, workflow and automation needs for each facility.  

For more information: www.penrad.com 

Related Content

World's largest radiation oncology meeting will offer full conference on interactive platform October 25-28, 2020
News | ASTRO | July 09, 2020
July 9, 2020 — Registration opens today for the American Society for Radiation Oncology's (...

Image courtesy of GE Healthcare

Feature | Mobile C-Arms | July 08, 2020 | By Melinda Taschetta-Millane
Moblie C-arms have seen several advances over the past de
 Many patients with severe coronavirus disease 2019 (COVID-19) remain unresponsive after surviving critical illness. Investigators led by a team at Massachusetts General Hospital (MGH) now describe a patient with severe COVID-19 who, despite prolonged unresponsiveness and structural brain abnormalities, demonstrated functionally intact brain connections and weeks later he recovered the ability to follow commands

Getty Images

News | Coronavirus (COVID-19) | July 08, 2020
July 8, 2020 — Many patients with severe coronavirus disease 2019 (...
Changes outlined in new draft U.S. Preventive Services Task Force (USPSTF) lung cancer screening recommendations will greatly increase the number of Americans eligible for screening and help medical providers save thousands more lives each year.

Image courtesy of Cerner

News | Lung Imaging | July 08, 2020
July 8, 2020 — Changes outlined in new draft U.S.
This is Figure 2 from the article in Radiology: Acute encephalopathy. A 60 year-old-man without history of seizures presenting with convulsion. (A-B) Multifocal areas of FLAIR hyperintensity in the right cerebellum (arrows in A), left anterior cingular cortex and superior frontal gyrus (arrows in B). (C-D) Restricted diffusion in the left anterior cingulate cortex, superior frontal and middle temporal gyrus (arrows in D) and right cerebellum (arrows in E), consistent with cerebellar diaschisis. F)  #COVID19

This is Figure 2 from the article in Radiology: Acute encephalopathy. A 60 year-old-man without history of seizures presenting with convulsion. (A-B) Multifocal areas of FLAIR hyperintensity in the right cerebellum (arrows in A), left anterior cingular cortex and superior frontal gyrus (arrows in B). (C-D) Restricted diffusion in the left anterior cingulate cortex, superior frontal and middle temporal gyrus (arrows in D) and right cerebellum (arrows in E), consistent with cerebellar diaschisis. F) No hemosiderin deposits in gradient echo sequences.

Feature | Coronavirus (COVID-19) | July 06, 2020 | Dave Fornell, Editor
Four recent radiology studies, from New York, Italy, Iran and China, show how...
This data represents wave 2 of a QuickPoLL survey conducted in partnership with an imagePRO panel created by The MarkeTech Group (TMTG), regarding the effects of COVID-19 on their business

Getty Images

Feature | Coronavirus (COVID-19) | July 01, 2020 | By Melinda Taschetta-Millane
Imaging Artificial Intelligence (AI) provider Qure.ai announced its first US FDA 510(k) clearance for its head CT scan product qER. The US Food and Drug Administration's decision covers four critical abnormalities identified by Qure.ai's emergency room product.
News | Artificial Intelligence | June 30, 2020
June 30, 2020 — Imaging Artificial Intelligence (AI) provider Qure.ai announced its first US FDA 510(k) clearance for